IL139843A0 - Topical administration of oxazolidinones for transdermal delivery - Google Patents

Topical administration of oxazolidinones for transdermal delivery

Info

Publication number
IL139843A0
IL139843A0 IL13984399A IL13984399A IL139843A0 IL 139843 A0 IL139843 A0 IL 139843A0 IL 13984399 A IL13984399 A IL 13984399A IL 13984399 A IL13984399 A IL 13984399A IL 139843 A0 IL139843 A0 IL 139843A0
Authority
IL
Israel
Prior art keywords
topical administration
oxazolidinones
transdermal delivery
infections
bacteremia
Prior art date
Application number
IL13984399A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL139843A0 publication Critical patent/IL139843A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13984399A 1998-06-05 1999-05-26 Topical administration of oxazolidinones for transdermal delivery IL139843A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828398P 1998-06-05 1998-06-05
PCT/US1999/010463 WO1999062504A2 (en) 1998-06-05 1999-05-26 Topical administration of oxazolidinones for transdermal delivery

Publications (1)

Publication Number Publication Date
IL139843A0 true IL139843A0 (en) 2002-02-10

Family

ID=22210475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13984399A IL139843A0 (en) 1998-06-05 1999-05-26 Topical administration of oxazolidinones for transdermal delivery

Country Status (29)

Country Link
US (2) US6613349B2 (pt)
EP (1) EP1083900B1 (pt)
JP (1) JP2002516852A (pt)
KR (1) KR100626781B1 (pt)
CN (1) CN1168447C (pt)
AT (1) ATE220548T1 (pt)
AU (1) AU749523B2 (pt)
BR (1) BR9910318A (pt)
CA (1) CA2327326A1 (pt)
CO (1) CO5011042A1 (pt)
CZ (1) CZ292420B6 (pt)
DE (1) DE69902170T2 (pt)
DK (1) DK1083900T3 (pt)
EA (1) EA003699B1 (pt)
ES (1) ES2179658T3 (pt)
HK (1) HK1036593A1 (pt)
HU (1) HU225234B1 (pt)
ID (1) ID23775A (pt)
IL (1) IL139843A0 (pt)
MY (1) MY122454A (pt)
NO (1) NO20006161D0 (pt)
NZ (1) NZ508636A (pt)
PL (1) PL193535B1 (pt)
PT (1) PT1083900E (pt)
SK (1) SK285352B6 (pt)
TR (1) TR200003205T2 (pt)
TW (1) TWI224000B (pt)
WO (1) WO1999062504A2 (pt)
ZA (1) ZA200005886B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562820B2 (en) 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
US20030096850A1 (en) * 2001-10-11 2003-05-22 Ford Charles W. Treating infections by administration of oxazolidinones
CA2476545A1 (en) * 2002-03-29 2003-10-16 Pharmacia & Upjohn Company Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4507287A (en) 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
JP2558107B2 (ja) 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JP3176626B2 (ja) 1991-11-01 2001-06-18 ファルマシア・アンド・アップジョン・カンパニー 抗菌剤として有用な置換アリール−およびヘテロアリールフェニルオキサゾリジノン類
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DK0730591T3 (da) 1993-11-22 2000-01-31 Upjohn Co Estere af substituerede hydroxyacetyl-piperazin-phenyl-oxazolidinoner
DE4425612A1 (de) 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
CA2198390C (en) 1994-09-14 2009-08-11 James E. Garbe Matrix for transdermal drug delivery
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
US5929086A (en) 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
EP0898477B1 (en) 1996-05-10 2002-12-18 PHARMACIA & UPJOHN COMPANY Topical administration of premafloxacin for the treatment of systemic bacterial diseases
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
US6312715B1 (en) 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain

Also Published As

Publication number Publication date
EA003699B1 (ru) 2003-08-28
KR100626781B1 (ko) 2006-09-22
CO5011042A1 (es) 2001-02-28
HUP0102191A2 (hu) 2002-05-29
DE69902170D1 (de) 2002-08-22
HK1036593A1 (en) 2002-01-11
ES2179658T3 (es) 2003-01-16
NZ508636A (en) 2002-03-01
US20020009483A1 (en) 2002-01-24
NO20006161L (no) 2000-12-04
ATE220548T1 (de) 2002-08-15
WO1999062504A3 (en) 2000-02-24
EP1083900A2 (en) 2001-03-21
PT1083900E (pt) 2002-12-31
EA200100010A1 (ru) 2001-06-25
CZ20004432A3 (cs) 2001-03-14
MY122454A (en) 2006-04-29
DK1083900T3 (da) 2002-11-04
EP1083900B1 (en) 2002-07-17
CN1298302A (zh) 2001-06-06
US6613349B2 (en) 2003-09-02
HU225234B1 (en) 2006-08-28
PL345119A1 (en) 2001-12-03
ID23775A (id) 2000-05-11
TR200003205T2 (tr) 2001-05-21
JP2002516852A (ja) 2002-06-11
HUP0102191A3 (en) 2003-07-28
US7892574B2 (en) 2011-02-22
ZA200005886B (en) 2002-04-22
KR20010052555A (ko) 2001-06-25
WO1999062504A2 (en) 1999-12-09
AU749523B2 (en) 2002-06-27
CN1168447C (zh) 2004-09-29
TWI224000B (en) 2004-11-21
AU4184899A (en) 1999-12-20
SK285352B6 (sk) 2006-11-03
DE69902170T2 (de) 2003-03-13
NO20006161D0 (no) 2000-12-04
CA2327326A1 (en) 1999-12-09
US20040072841A1 (en) 2004-04-15
SK16262000A3 (sk) 2001-06-11
PL193535B1 (pl) 2007-02-28
CZ292420B6 (cs) 2003-09-17
BR9910318A (pt) 2001-01-30

Similar Documents

Publication Publication Date Title
Reyzelman et al. Are antibiotics necessary in the treatment of locally infected ingrown toenails?
EP1330221A4 (en) PHARMACEUTICAL COMPOSITIONS, DRESSINGS AND METHODS FOR TREATING MICROBIAL INFECTIONS OF SKIN LESIONS
HUP9901991A2 (hu) Transzdermális eszköz flurbiprofén átadására
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AU5056196A (en) Hydrogel-forming, self-solvating absorbable polyester copolymers and methods for use thereof
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
Nolting Non-traumatic removal of the nail and simultaneous treatment of onychomycosis
IL139843A0 (en) Topical administration of oxazolidinones for transdermal delivery
DK1135020T3 (da) Bipest-behandlinger
SG125079A1 (en) Oxazolidinones to treat eye infections
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
ECSP992967A (es) Aplicación topica de oxazolidinonas para administracion transdermica
Avinash et al. Comparative evaluation of efficacy of controlled release local drug delivery system and local irrigation of chlorhexidine gluconate following scaling and root planing-Clinical study
SE9903499D0 (sv) Antimicrobial agent for treatment and prophylaxis
CA2343471A1 (en) Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy
TNSN03022A1 (en) Method for treatment of inflammation
Nolling Non-Traumatic Removal of the Nail and Simultaneous Treatment of Onychomycosis
TH57851B (th) การให้ออกซาโซลิดิโนนเฉพาะที่สำหรับการส่งผ่านทางผิวหนัง
RU99110181A (ru) Способ профилактики нагноения донорской раны после забора расщепленного кожного аутотрансплантата у больных с послеоперационными грыжами при наличии очагов хронической инфекции
TH57851A3 (th) การให้ออกซาโซลิดิโนนเฉพาะที่สำหรับการส่งผ่านทางผิวหนัง